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Abstract
The prevalence of masked hypertension, out-of-clinic daytime systolic/diastolic blood pressure 
(SBP/DBP)≥135/85 mmHg on ambulatory blood pressure monitoring (ABPM) among adults with 
clinic SBP/DBP<140/90 mmHg, is high. It is unclear who should be screened for masked 
hypertension. We derived a clinic blood pressure (CBP) index to identify populations for masked 
hypertension screening. Index cut-points corresponding to 75% to 99% sensitivity and 
prehypertension were evaluated as ABPM testing criterion. In a derivation cohort (n=695), the 
index was clinic SBP+1.3*clinic DBP. In an external validation cohort (n=675), the sensitivity for 
masked hypertension using an index ≥190 mmHg and ≥217 mmHg and prehypertension status was 
98.5%, 71.5% and 82.5%, respectively. Using NHANES data (n=11,778), we estimated that these 
thresholds would refer 118.6, 44.4 and 59.3 million US adults, respectively, to ABPM screening 
for masked hypertension. In conclusion, the CBP index provides a useful approach to identify 
candidates for masked hypertension screening using ABPM.
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INTRODUCTION
In 2002, Pickering introduced the term masked hypertension, referring to individuals not 
taking antihypertensive medication who have non-elevated clinic-measured blood pressure 
(BP) but elevated daytime BP when assessed outside of the clinic by ambulatory blood 
pressure monitoring (ABPM).1 Masked daytime hypertension has been reported to be 
common among individuals with non-elevated clinic BP (CBP) with prevalence estimates 
ranging from 15% to 30% in population-based studies.2 Compared with sustained 
normotension, defined as non-elevated CBP with non-elevated daytime BP on ABPM, 
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masked daytime hypertension is associated with increased risk for target-organ damage, 
cardiovascular disease and mortality.3,4
Some guidelines and position papers recommend ABPM to detect masked hypertension.5–7 
However, it is unclear which populations to screen with ABPM to detect masked 
hypertension.5–21 One approach would be to offer ABPM to all adults with non-elevated 
CBP to identify those with masked hypertension.2 However, population-wide screening for 
masked hypertension is not practical. Another approach is to offer ABPM to individuals 
with prehypertension, defined as clinic systolic BP (SBP) of 120–139 mmHg or clinic 
diastolic BP (DBP) of 80–89 mmHg, due to the substantial overlap that exists between 
prehypertension and masked hypertension.22,23 This too may result in a substantial 
proportion of US adults undergoing ABPM. A third approach is to develop an equation to 
identify individuals for ABPM screening.
In this study, we derived and validated a CBP diagnostic index for detecting masked 
hypertension among adults with non-elevated CBP who were not taking antihypertensive 
medication. Test characteristics for the identification of masked hypertension using this 
index, including sensitivity, specificity, and positive and negative predictive values, were 
calculated and compared with the test characteristics associated with using prehypertension. 
Data from the National Health and Nutrition Examination Survey (NHANES) 2009–2012 
were used to estimate the number of US adults who would be recommended having ABPM 
to detect masked hypertension using each of these approaches.
METHODS
Study Populations
The current analyses used data from four studies. The Masked Hypertension (MHT) Study 
(n=1,010) was used to derive an equation, the CBP diagnostic index, for identifying masked 
daytime hypertension.22 We pooled the Improving the Detection of Hypertension (IDH) 
Study (n=408) and the Jackson Heart Study (JHS; n=5,301; n=1,148 who completed ABPM) 
to externally validate the CBP diagnostic index in samples having a high number of 
Hispanics and African Americans. NHANES 2009–2010 and 2011–2012 (n=11,778) were 
used to estimate the number of US adults ≥20 years old that would be recommended ABPM 
screening to identify masked hypertension with the approaches being compared.
Each of the studies used for the current analysis have been described in detail 
previously.22,24–26 In brief, the MHT Study is a worksite-based study comprised of adult 
employees from Stony Brook University, University Hospital at Stony Brook, Columbia 
University, and a private hedge fund management organization in New York who work >20 
hours per week and on at least two consecutive days. The goal of the MHT Study is to 
estimate the prevalence, predictors, and prognosis of masked hypertension.22 The IDH Study 
enrolled a community-based sample of adults, primarily from upper Manhattan, New York 
City.24 It was designed to compare the cost-effectiveness of different strategies for 
diagnosing ambulatory hypertension. The JHS is a prospective population-based study 
comprised exclusively of African Americans from the tri-county (Hinds, Madison and 
Rankin counties) area of Jackson, MS.25 The purpose of the JHS is to evaluate 
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cardiovascular disease risk among African Americans.27 The aim of the NHANES is to 
assess the health and nutritional status of adults and children in the US. The NHANES 
enrolled a multistage probability sample of non-institutionalized U.S. civilians and can be 
used to calculate nationally representative estimates of disease prevalence. It is conducted in 
2 year cycles and these cycles can be pooled to provide stable prevalence estimates in 
population sub-groups.
For the current analyses, the MHT Study, the IDH Study and the JHS were restricted to 
participants who met criteria for a complete ABPM (defined below) and who had non-
elevated CBP and were not taking antihypertensive medication (MHT Study: n=695; IDH 
Study: n=344; JHS: n=331). The NHANES sample was restricted to participants ≥20 years 
of age who had non-elevated CBP and were not taking antihypertensive medication 
(n=6,835). ABPM was not performed in the NHANES. Additional details on each study are 
available in the online eSupplement. The current study was approved by all appropriate 
Institutional Review Boards and is in agreement with the Declaration of Helsinki. All 
participants provided written informed consent.
Data collection
The MHT and IDH studies collected data using self-administered questionnaires during a 
clinic examination and through ABPM. The JHS collected data using interviewer-
administered questionnaires during a clinic examination and through ABPM. In each study, 
trained technicians measured height, weight and CBP during a clinic examination. 
Questionnaires were used to document information on demographics (i.e., age, sex, race/
ethnicity), smoking status, current use of antihypertensive medication and self-reported 
diabetes status. In the NHANES, interviewer-administered questionnaires were used during 
the in-home interview to collect demographic information and data on antihypertensive 
medication use.
Clinic blood pressure in the MHT Study, IDH Study, JHS and NHANES
In all four studies, CBP was measured by trained staff following a standardized protocol. 
Prior to CBP measurements, participants sat quietly for at least 5 minutes in an upright 
position with their back and arms supported, feet flat on the floor and legs uncrossed. During 
the CBP measurements, an appropriately-sized cuff, determined by measuring the mid-arm 
circumference, was used.28,29 One-to-two minutes elapsed between the readings in the MHT 
Study, IDH Study and JHS; there was a 30-second interval between the readings in the 
NHANES. In the MHT Study, IDH Study and NHANES, three CBP measurements were 
obtained using a mercury sphygmomanometer. In the JHS, two CBP measurements were 
obtained using a random zero mercury sphygmomanometer. For each participant, the CBP 
measurements were averaged. Non-elevated CBP was defined as clinic SBP<140 mmHg and 
clinic DBP<90 mmHg. Prehypertension was defined as clinic SBP of 120–139 mmHg or 
clinic DBP of 80–89 mmHg.
Ambulatory blood pressure monitoring in the MHT Study, IDH Study and JHS
ABPM was conducted in the MHT Study, IDH Study and JHS using Spacelabs Model 
90207 (Snoqualmie, WA). For each study, participants were fitted with an appropriately-
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sized ABPM arm cuff. BP on ABPM was recorded every 28 minutes in the MHT Study, 
every 30 minutes in the IDH Study and every 20 minutes in the JHS. For the current 
analysis, we defined diurnal periods using International Database on ABPM in relation to 
Cardiovascular Outcomes (IDACO) criteria. Daytime was defined as the time period from 
10:00 to 20:00 and nighttime as 00:00 to 06:00.30 Participants were considered to have a 
complete ABPM if they had ≥10 daytime and ≥5 nighttime SBP and DBP measurements.
The ABPM recordings were analyzed to obtain mean daytime and nighttime SBP and DBP. 
Daytime hypertension was defined as a mean SBP ≥ 135 mmHg or mean DBP ≥ 85 mmHg 
based on the daytime measurements, and nocturnal hypertension was defined as a mean SBP 
≥ 120 mmHg or mean DBP ≥ 70 mmHg based on the nighttime measurements.5,31,32 Since 
the current analysis was restricted to participants with non-elevated CBP, those with daytime 
and nocturnal hypertension had masked daytime hypertension and masked nocturnal 
hypertension, respectively.
Statistical Analyses
In the MHT Study, the c-statistic was calculated for three logistic regression models to 
identify factors that discriminated participants with and without masked daytime 
hypertension, defined as a mean daytime SBP ≥ 135 mmHg or mean daytime DBP ≥ 85 
mmHg in participants with non-elevated CBP (SBP/DBP <140/90 mmHg; Supplemental 
eTable 1).33 In these analyses, masked daytime hypertension was the dependent variable. 
The independent variables were clinic SBP and DBP in Model 1; age, sex, body mass index, 
race, ethnicity, diabetes and current smoking in Model 2; and all variables from Models 1 
and 2 in Model 3. As described below, Model 1 discriminated masked daytime hypertension 
better than Model 2. Discrimination was better in Model 3 versus Model 1. Model 1 was 
chosen for the diagnostic index as it provides a simple method using CBP alone and may be 
more easily implemented in practice.
A receiver operating characteristic curve was plotted to determine the CBP diagnostic index 
cut-point with 99%, 95%, 90%, 85%, 80% and 75% sensitivity (Supplemental eFigure 1). 
The CBP diagnostic index cut-point for masked daytime hypertension corresponding to the 
respective sensitivity level was subsequently applied in the diagnostic index equation from 
the selected logistic regression model (Model 1) to derive the cut-points. The online 
eSupplement provides further details on the derivation of the CBP diagnostic index.
In the pooled IDH/JHS validation cohort, the c-statistic and the Hosmer-Lemeshow 
Goodness-of-Fit for deciles were calculated to determine the discrimination and calibration, 
respectively, of the diagnostic index. The external validity of the CBP diagnostic index was 
determined by taking the cut-points associated with 99%, 95%, 90%, 85%, 80% and 75% 
sensitivity from the MHT Study and calculating the test characteristics for detecting masked 
daytime hypertension in the pooled IDH/JHS validation cohort. As the 2013 European 
Society of Hypertension (ESH) position paper on ABPM recommends including nocturnal 
hypertension as a criterion for the definition of masked hypertension, we evaluated the test 
characteristics of the CBP diagnostic index for identifying masked daytime or masked 
nocturnal hypertension in a secondary analysis.5 For comparison, test characteristics were 
calculated for prehypertension and the upper range of prehypertension (i.e., clinic SBP 130–
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139 mmHg or clinic DBP 85–89 mmHg). The upper range of prehypertension was selected 
for an a priori analysis as studies have reported that the prevalence of masked hypertension 
is very high in this range of CBP.4,22,34
Finally, using the NHANES 2009–2012 data, the number and percentage of US adults ≥20 
years old who would be recommended testing with ABPM was estimated for individuals 
with an elevated CBP diagnostic index, prehypertension, and the upper range of 
prehypertension, separately. Estimates were calculated for the overall population and in sub-
groups defined by age (i.e., <40, 40–59, ≥60 years), race/ethnicity (i.e., non-Hispanic white, 
non-Hispanic black, Hispanic, other) and sex. NHANES analyses were conducted taking 
into account the study’s complex multistage sampling design and were weighted to produce 
US population estimates. Analyses were conducted using SAS version 9.4 (SAS Institute, 
Cary, NC) and SUDAAN 10.1 (Research Triangle Institute, Research Triangle Park, NC).
RESULTS
Participant characteristics
Compared with the derivation cohort (i.e., MHT Study), the pooled validation cohort (i.e., 
IDH/JHS) had a higher percentage of participants who were aged 60 years or older, and 
black and Hispanic (Table 1). Participants with prehypertension and the upper range of 
prehypertension comprised 39.9% and 12.8% of the derivation cohort, respectively, and 
47.4% and 19.3% of the pooled validation cohort, respectively. Whereas masked daytime 
and masked nocturnal hypertension was present in 19.3% and 20.0% of the derivation 
cohort, respectively, the prevalence was 20.3% and 32.9%, respectively, in the pooled 
IDH/JHS cohort. Also, 30.2% and 37.6% of the MHT and pooled IDH/JHS cohort 
participants, respectively, had masked daytime and/or nocturnal hypertension.
Derivation of the clinic blood pressure diagnostic index in the Masked Hypertension Study
The c-statistic (95% confidence interval [CI]) for masked daytime hypertension was 0.78 
(95% CI 0.74–0.82) for a model including only clinic SBP and DBP (Model 1) and 0.72 
(95% CI 0.66–0.77) for a model that included age, sex, body mass index, race, ethnicity, 
diabetes, and current smoking status (Model 2; Supplemental eTable 1). In a model 
including all of the variables from Models 1 and 2 (Model 3), the c-statistic was 0.81 (95% 
CI 0.77–0.85). Using Model 1, the CBP diagnostic index was defined as: clinic SBP 
+ 1.3*clinic DBP.
A scatterplot of each participant’s clinic SBP and DBP in the MHT Study is shown in 
Supplemental eFigure 2. The lines in the figure correspond to the CBP diagnostic index 
equation for sensitivity levels of 99%, 95%, 90%, 85%, 80% and 75%. Using the CBP 
diagnostic index equation, the cut-point for detecting masked daytime hypertension with 
99% sensitivity was 190 mmHg. The cut-point for 95% sensitivity was 201 mmHg, 90% 
sensitivity was 207 mmHg, 85% sensitivity was 212 mmHg, 80% sensitivity was 214 mmHg 
and 75% sensitivity was 217 mmHg. The specificity and positive and negative predictive 
values for each level of sensitivity are provided in Supplemental eTable 2.
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Validation of the clinic blood pressure diagnostic index in the pooled IDH/JHS cohorts
In the validation cohort, the c-statistic (95% confidence interval [CI]) for masked daytime 
hypertension was 0.77 (95% CI 0.73–0.81). The CBP diagnostic index was well calibrated 
in the validation cohort (Hosmer-Lemeshow Goodness-of-Fit chi-square for deciles with 8 
degrees of freedom: 9.78; p=0.281). A scatterplot of IDH and JHS participants’ clinic SBP 
and DBP readings and the boundary lines representing 99%, 95%, 90%, 85%, 80% and 75% 
sensitivity for detecting masked daytime hypertension using the CBP diagnostic index are 
plotted in Figure 1. In the pooled IDH/JHS cohort, the sensitivity for detecting masked 
daytime hypertension using the cut-points on the CBP diagnostic index from the MHT study 
ranged from 98.5% to 71.5% and the specificity ranged from 18.8% to 64.1%, respectively 
(CBP diagnostic index ≥190 mmHg to ≥217 mmHg, respectively; Table 2, top panel). The 
sensitivity and specificity for detecting masked daytime hypertension was 82.5% and 61.5% 
for prehypertension and 42.3% and 86.6% for the upper range of prehypertension, 
respectively. The sensitivity for detecting masked daytime or nocturnal hypertension ranged 
from 97.2% to 64.6% (CBP diagnostic index ≥190 mmHg to ≥217 mmHg, respectively) 
using the CBP diagnostic index and was 71.3% for prehypertension and 34.3% for the upper 
range of prehypertension (Table 2, bottom panel).
Testing for masked daytime hypertension in the US population
In 2009–2012, an estimated 152.7 million US adults had non-elevated CBP and were not 
taking antihypertensive medication (Table 3). Using the CBP diagnostic index, the number 
of US adults recommended ABPM to detect masked daytime hypertension ranged from 44.4 
million using a cut-point of 217 mmHg to 118.6 million using a cut-point of 190 mmHg. 
Using prehypertension as the criterion for ABPM would result in referring 59.3 million US 
adults for ABPM. There would be 20.3 million US adults referred for ABPM if the upper 
range of prehypertension is used.
DISCUSSION
In the current study, we developed and validated a CBP diagnostic index that identifies 
adults as having masked daytime hypertension. We externally validated cut-points for 
identifying masked daytime hypertension using the CBP diagnostic index with sensitivity 
ranging from 75% to 99%. Although the CBP diagnostic index can be used to identify 
almost all adults with masked hypertension (i.e., approximately 99% sensitivity), this would 
require that 118.6 of the 152.7 million US adults with non-elevated CBP undergo ABPM. 
By choosing a cut-point associated with lower sensitivity, specificity would be higher and 
ABPM would be required for far fewer US adults. For example, using a cut-point that 
identified 89.8% of individuals with masked daytime hypertension would require testing 
73.1 million US adults. For comparison, using prehypertension as a criterion to screen for 
masked daytime hypertension provides 82.5% sensitivity and would require 59.3 million US 
adults undergo ABPM. While the upper range of prehypertension would only require 
screening 20.3 million US adults, less than 50% of masked daytime hypertension cases 
(42.3% sensitivity) would be referred to ABPM.
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Guidelines and position papers recommend ABPM to detect masked hypertension but 
agreement has not been reached on who should be offered ABPM.2,5–21 The current study 
provides evidence that it is impractical to perform ABPM on all US adults (approximately 
153 million) with non-elevated CBP who were not taking antihypertensive medication. A 
more reasonable approach would be to test adults with a CBP diagnostic index above a 
specified cut-point. For any selected cut-point, there is a balance between sensitivity to 
detect masked daytime hypertension and the number of US adults requiring testing with 
ABPM. Using a low cut-point provides high sensitivity and almost all adults with masked 
daytime hypertension would be detected. However, this would result in performing ABPM 
on a majority of US adults with non-elevated CBP. In contrast, using a higher cut-point on 
the CBP diagnostic index, the sensitivity will be lower but substantially fewer US adults 
would need to undergo ABPM.
There are proponents of offering ABPM to adults with prehypertension in order to detect 
masked hypertension.22,34 Supporting this approach are prior studies that have examined the 
overlap of prehypertension with masked daytime hypertension.22 In the MHT Study, 35.0% 
of participants with prehypertension but only 8.9% of those with normal CBP had masked 
daytime hypertension.22 Similarly, masked daytime hypertension was more common among 
IDH/JHS participants with prehypertension (35.3%) compared to normal CBP (6.8%).35 In 
the MHT Study, masked daytime hypertension was almost twice as common in adults with 
CBP in the upper versus lower range of prehypertension (i.e. clinic SBP/DBP 130–139/85–
89 mmHg versus 120–129/80–84 mmHg): 51.7% versus 26.5%.22 These studies may be 
interpreted as recommending ABPM for adults with CBP in the upper range of 
prehypertension may be an appropriate approach for detecting masked hypertension. 
Although these prior studies demonstrate high positive predictive value of prehypertension 
to identify masked daytime hypertension, the current study shows the upper range of 
prehypertension has low sensitivity for detecting masked daytime hypertension. Therefore, 
referring only individuals with CBP in the upper range of prehypertension for ABPM would 
miss the majority of individuals with masked daytime hypertension.
Increasing evidence suggests that CVD risk is higher for individuals with compared to 
without elevated nighttime BP.36 The 2013 European Society of Hypertension ABPM 
position paper incorporates elevated nighttime BP as a criterion for masked hypertension. 
The current study suggests that the cut-points from the CBP diagnostic index chosen for 
detecting masked daytime hypertension may also be useful for detecting masked daytime or 
nocturnal hypertension.
ABPM and home blood pressure monitoring (HBPM) can also be used to identify masked 
hypertension. Some evidence suggests that some individuals have masked hypertension on 
ABPM or HBPM, but not by both approaches. It is unclear whether the current results apply 
to masked hypertension identified by HBPM.
The current study has several strengths. First, there were four cohorts available for analysis. 
This allowed us to derive the CBP diagnostic index, externally validate it and estimate the 
number of US adults that would be recommended for ABPM across a range of cut-points on 
the index. The large number of participants from each cohort with non-elevated CBP 
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provided large samples to derive and externally validate the CBP diagnostic index. 
Furthermore, these cohorts allowed us to compare test characteristics for cut-points on the 
CBP diagnostic index with prehypertension and the upper range of prehypertension. 
Additionally, the pooled validation cohort had a high representation of minorities including 
Hispanics in IDH and African Americans in the JHS.
Several limitations should be considered when interpreting the current results. Although the 
CBP diagnostic index was validated in a pooled cohort of IDH Study and JHS participants, it 
may not be generalizable to other populations. Masked hypertension was diagnosed using 
one 24-hour ABPM period. While some individuals with masked daytime and/or nocturnal 
hypertension on a single ABPM may not have it when repeated, conducting only one 24-
hour ABPM period is common clinical practice.24 The cut-points may be different if an 
oscillometric device were used to measure CBP. Also, while all four studies used trained 
staff who followed standardized protocols to measure CBP, the effect of different intervals 
on successive CBP measurements (e.g., 30-seconds in the NHANES versus 1–2 minutes in 
other studies) is unclear. Further, CBP was measured following a research protocol in each 
of the individual studies. However, CBP measured in clinical practice is generally of poorer 
quality. Last, a possible limitation of the use of ABPM in clinical practice is that self-
reported sleep disturbances are relatively common among those who undergo ABPM.
There are approximately 153 million adults with non-elevated CBP who are not taking 
antihypertensive medication in the US. Performing ABPM on all of these people in order to 
detect masked hypertension is not practical. Using the CBP diagnostic index, developed and 
validated in the current study, provides a simple approach to identify a sub-group of 
individuals for whom ABPM is better targeted. If identifying all individuals with masked 
hypertension is viewed as necessary, a cut-point of 190 mmHg on the CBP diagnostic index 
could be used. NHANES data indicate that 118.6 million US adults would be referred for 
ABPM under this approach. In contrast, fewer US adults would be referred to ABPM using 
higher cut-points on the CBP diagnostic index, but at the expense of lower sensitivity. The 
use of the upper range of prehypertension as screening criteria would result in masked 
hypertension not being identified in many people. In conclusion, the current study provides 
empirical data on various approaches for identifying masked hypertension in untreated 
adults with non-elevated CBP.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Scatterplot of clinic systolic versus diastolic blood pressure demonstrating derived cut-points 
corresponding with specified sensitivity levels for detecting masked daytime hypertension 
using the clinic blood pressure index equation in the pooled validation cohort of Improving 
the Detection of Hypertension Study and Jackson Heart Study participants (n=675).
The shaded region represents the clinic blood pressure values corresponding with 
prehypertension defined as systolic blood pressure ≥ 120 mmHg and < 140 mmHg and/or 
diastolic blood pressure ≥ 80 mmHg and < 90 mmHg.
Region A: The clinic blood pressure diagnostic index, defined as systolic clinic blood 
pressure + 1.3*diastolic clinic blood pressure, was categorized as normal (i.e., below the cut-
point corresponding with the specified sensitivity level).
Region B: The clinic blood pressure diagnostic index, defined as systolic clinic blood 
pressure + 1.3*diastolic clinic blood pressure, was categorized as elevated (i.e., at or above 
the cut-point corresponding with the specified sensitivity level).
Cut-points for an elevated clinic blood pressure diagnostic index corresponding with the 
specified sensitivity levels:
Sensitivity 99%: ≥ 190 mmHg.
Sensitivity 95%: ≥ 201 mmHg.
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Sensitivity 90%: ≥ 207 mmHg.
Sensitivity 85%: ≥ 212 mmHg.
Sensitivity 80%: ≥ 214 mmHg.
Sensitivity 75%: ≥ 217 mmHg.
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Table 1
Characteristics of the Masked Hypertension Study, Improving the Detection of Hypertension Study and 
Jackson Heart Study participants.
MHT Study
(derivation cohort)
IDH/JHS
(pooled validation cohort)
(n=695) (n=675)
Age categories
  < 40 years 213 (30.7%) 212 (31.4%)
  40 to 59 years 435 (62.6%) 324 (48.0%)
  ≥ 60 years 47 (6.8%) 139 (20.6%)
Male 275 (39.6%) 241 (35.9%)
Black race 47 (6.8%) 5415 (61.5%)
Hispanic ethnicity 87 (12.5%) 216 (32.0%)
Body mass index, kg/m2 27.4 (5.4%) 28.5 (6.0)
Diabetes 25 (3.8%) 37 (5.5%)
Current smoker 49 (7.4%) 62 (9.3%)
Clinic blood pressure
  Systolic, mmHg 113.8 (10.7) 115.0 (11.8)
  Diastolic, mmHg 74.4 (7.5) 74.3 (8.0)
  Prehypertensiona 277 (39.9%) 320 (47.4%)
  Upper range of prehypertensionb 89 (12.8%) 130 (19.3%)
Ambulatory blood pressure
  Daytime period
    Systolic, mmHg 122.6 (10.1) 118.6 (12.1)
    Diastolic, mmHg 77.2 (7.5) 71.8 (9.4)
    Masked daytime hypertensionc 134 (19.3%) 137 (20.3%)
  Nighttime period
    Systolic, mmHg 106.2 (10.7) 108.6 (11.1)
    Diastolic, mmHg 62.3 (7.9) 63.5 (7.7)
    Masked nocturnal hypertensiond 139 (20.0%) 222 (32.9%)
    Masked daytimec and/or nocturnald hypertension 210 (30.2%) 254 (37.6%)
Numbers in the table are number (percentage) or mean (standard deviation).
MHT: Masked Hypertension Study.
IDH: Improving the Detection of Hypertension Study.
JHS: Jackson Heart Study.
a
Prehypertension: Among adults with non-elevated clinic blood pressure (i.e., systolic blood pressure < 140 mmHg and diastolic blood pressure < 
90 mmHg), clinic systolic blood pressure ≥ 120 mmHg and < 140 mmHg or clinic diastolic blood pressure ≥ 80 mmHg and < 90 mmHg.
bUpper range of prehypertension: Among adults with non-elevated clinic blood pressure (i.e., systolic blood pressure < 140 mmHg and diastolic 
blood pressure < 90 mmHg), clinic systolic blood pressure ≥ 130 mmHg and < 140 mmHg or clinic diastolic blood pressure ≥ 85 mmHg and < 90 
mmHg.
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c
Masked daytime hypertension: Clinic systolic/diastolic blood pressure < 140/90 mmHg with mean ambulatory daytime systolic/diastolic blood 
pressure ≥ 135/85 mmHg.
d
Masked nocturnal hypertension: Clinic systolic blood pressure < 140/90 mmHg with mean ambulatory nocturnal systolic/diastolic blood pressure 
≥ 120/70 mmHg.
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